Which psychopathological condition is Brexpiprazole (Rexulti) FDA approved for?

Brexpiprazole, marketed under the brand name Rexulti, is primarily FDA-approved for the treatment of schizophrenia. It is an atypical antipsychotic that operates by modulating dopamine and serotonin receptors in the brain, which can significantly help manage the symptoms associated with schizophrenia, such as delusions, hallucinations, and disorganized thinking.

While Brexpiprazole is also approved for use as an adjunctive treatment for major depressive disorder and has been explored for applications in other conditions, its specific FDA approval for schizophrenia underscores its central role in treating this particular disorder. This approval highlights its efficacy in alleviating symptoms and improving overall patient functioning in individuals diagnosed with schizophrenia.